Clinical Trial TitleThe RED-C Study: A Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion Tablets for the Delay of Encephalopathy Decompensation in Patients with Cirrhosis
National Clinical Trial Number:NCT05071716
Clinical Trial Protocol Description:
The RED-C study is designed to assess how well Rifaximin soluble solid dispersion tablets work to delay hepatic encephalopathy (confusion due to liver cirrhosis) in patients with liver cirrhosis related to any kind of liver disease. Patients will need to attend regular research visits at the Rush downtown campus.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Have been diagnosed with liver cirrhosis with medically controlled ascites.
You will be excluded from the study if any of the following criteria apply to you:
- Have experienced an episode of hepatic encephalopathy in the past.
- Have taken or be taking rifaximin 550 mg and/or lactulose for a suspected hepatic encephalopathy episode.
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.